date:Oct 12, 2012
health and wellness market, which will soon represent 35% of its commercial activity. Nexira confirms its growth target of 125 million euros in consolidated sales by 2015.
We are pleased to welcome the Tournay Biotechnologies personnel, with whom we share family values. We are confident that this acquisition is aligned with the expansion plan that we announced one year ago said Stphane Dondain, President of Nexira.
The acquisition of Tournay Biotechnologies by Nexira will give to the company